Extended mortality results for prostate cancer screening in the PLCO trial with median follow-up of 15 years.

<h4>Background</h4>Two large-scale prostate cancer screening trials using prostate-specific antigen (PSA) have given conflicting results in terms of the efficacy of such screening. One of those trials, the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial, previously reported out... View More